HI-Bio

Braveheart files for IPO to support Hengrui-licensed cardio asset

Braveheart Bio isn’t letting Big Pharma take its freedom anytime soon as it aims for a Nasdaq listing to move its phase 3 cardiovascular drug forward.

Will Maddox Jul 15, 2026 1:40pm

Braveheart, with Biogen CEO on board, rallies $185M series A

Nov 5, 2025 7:51am

Biogen CEO said no risky deals in 2023. Now he’s ready to be bold

Aug 1, 2024 10:34am

illustration of two people putting puzzle pieces together merger and acquisition concept

Biogen inks $1.15B HI-Bio buyout to expand in immunology

May 22, 2024 8:24am

Joe Biden reportedly chooses NIH head—Chutes & Ladders

Apr 21, 2023 9:30am

Graphic image of a rocket rising above six balloons that are at the same level

HI-Bio's expectations elevated by phase 2 autoimmune readouts

Apr 11, 2023 6:00am